German Center for Neurodegenerative Diseases

Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program

Retrieved on: 
Wednesday, July 12, 2023
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, DZNE, Hannover Medical School, DFG, Ludwig Maximilian University of Munich, German Center for Neurodegenerative Diseases, University, Medicine, Department of Neurology, Xuanwu hospital, Parkinson, Doctor of Philosophy, Medication, Tauopathy, LMU, Translational Neurodegeneration, Amylyx Pharmaceuticals, Physics, German, AMX0035, Neurodegenerative disease, German Research Foundation, Death, PSP, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany, to discuss the treatment landscape for people living with progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany, to discuss the treatment landscape for people living with progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET.
  • Prof. Dr. Höglinger studied medicine and physics at the universities of Regensburg and Würzburg and earned his PhD in medicine, summa cum laude, in 2000.
  • Since 2011, he has held the Chair of the Department of Translational Neurodegeneration at the German Center for Neurodegenerative Diseases, DZNE.
  • For many years, Prof. Dr. Höglinger has been conducting translational research into tauopathies and was actively involved in many international clinical trials in PSP.

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Retrieved on: 
Monday, March 20, 2023
Vaccine, German Center for Neurodegenerative Diseases, ABATE, Personalized medicine, AC, Immunotherapy, Down syndrome, Plasma, Discovery, International Conference on Emerging Infectious Diseases, Neurodegenerative disease, Conference, Pharmaceutical industry

In addition, Johannes Streffer, M.D., Chief Medical Officer of AC Immune, will join an expert panel to discuss the latest developments in immunotherapies in Alzheimer’s disease.

Key Points: 
  • In addition, Johannes Streffer, M.D., Chief Medical Officer of AC Immune, will join an expert panel to discuss the latest developments in immunotherapies in Alzheimer’s disease.
  • Andrea Pfeifer, Ph.D., CEO of AC Immune SA, commented: “The ten presentations during this AD/PDTM conference demonstrate AC Immune’s progress towards our over-arching goal, which is to shift the treatment paradigm towards Precision Medicine and disease prevention.
  • As our clinical programs in Alzheimer’s and Parkinson’s diseases are advancing, we are solidifying our position as a leading developer of vaccines for neurodegenerative diseases.
  • AC Immune’s cutting-edge therapeutic and diagnostic research programs pursuing multiple validated molecular targets, highlight the breadth of our pipeline.

Rainwater Charitable Foundation Announces Fourth-Annual Rainwater Prize Winners for Brain Research

Retrieved on: 
Thursday, January 26, 2023
Miller, Conference, Presidential Early Career Award for Scientists and Engineers, Research group, Neurology, Washington University School of Medicine, FDA, Huntington's disease, Brain, Molecular medicine, Disease, Engineering, Innovation, DSM-IV codes, Tauopathy, DZNE, Biophysics, ASO, Nervous system, DRS, SMA, Biology, Neurodegenerative disease, Progressive supranuclear palsy, Neuron, Messenger, DNA, University of California, San Diego, UCSD, Alzheimer's disease, Washington University in St. Louis, Drug discovery, Cell, Tau, Parkinson's disease, University, ALS, German Center for Neurodegenerative Diseases, Distinguishing, Nusinersen, Rain, SOD1, Wegmann, Pharmaceutical industry, Research, Ionis

FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist. This year's Outstanding Innovation Prize will be awarded to a team: Dr. C. Frank Bennett, Ionis; Dr. Don W. Cleveland, University of California San Diego (UCSD); and Dr. Timothy M. Miller, Washington University. Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist. The prizes will be presented during the Eurotau 2023 Conference on April 27, 2023 in Lille, France.

Key Points: 
  • FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist.
  • Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist.
  • Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research will be shared by:
    Collaborators Drs.
  • "I could not be more excited about this year's winners of the Rainwater Prize," said Todd Rainwater, Trustee of the Rainwater Charitable Foundation.

Rainwater Charitable Foundation Announces Fourth-Annual Rainwater Prize Winners for Brain Research

Retrieved on: 
Thursday, January 26, 2023
Miller, Conference, Presidential Early Career Award for Scientists and Engineers, Research group, Neurology, Washington University School of Medicine, FDA, Huntington's disease, Brain, Molecular medicine, Disease, Engineering, Innovation, DSM-IV codes, Tauopathy, DZNE, Biophysics, ASO, Nervous system, DRS, SMA, Biology, Neurodegenerative disease, Progressive supranuclear palsy, Neuron, Messenger, DNA, University of California, San Diego, UCSD, Alzheimer's disease, Washington University in St. Louis, Drug discovery, Cell, Tau, Parkinson's disease, University, ALS, German Center for Neurodegenerative Diseases, Distinguishing, Nusinersen, Rain, SOD1, Wegmann, Pharmaceutical industry, Research, Ionis

FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist. This year's Outstanding Innovation Prize will be awarded to a team: Dr. C. Frank Bennett, Ionis; Dr. Don W. Cleveland, University of California San Diego (UCSD); and Dr. Timothy M. Miller, Washington University. Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist. The prizes will be presented during the Eurotau 2023 Conference on April 27, 2023 in Lille, France.

Key Points: 
  • FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist.
  • Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist.
  • Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research will be shared by:
    Collaborators Drs.
  • "I could not be more excited about this year's winners of the Rainwater Prize," said Todd Rainwater, Trustee of the Rainwater Charitable Foundation.

Dense Liquid Droplets Act as Cellular Computers

Retrieved on: 
Wednesday, September 14, 2022
Institute, NMR, Enzyme, American Cancer Society, Ribosome, MAPK3, Crowding, Acceleration, AT8, Department, DAAD, National, Neurodegeneration, NYU Langone Health, Q-system (genetics), Cyclin-dependent kinase 1, Neoplasm, TR01, Computer, European Research Council, Chan Zuckerberg Initiative, The German, Structural biology, National Institutes of Health, Max Planck Society, Biochemistry, MTORC1, Patient, Defense, Genetics, Protein, Cell, German Center for Neurodegenerative Diseases, NYU, Doctor of Philosophy, Research, Water, Kinase, DZNE, New York University Grossman School of Medicine, Alzheimer's disease, Phosphorylation, Phosphorus, Medical imaging, Pharmaceutical industry, Fine chemical, Molecular Cell

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- An emerging field explores how groups of molecules condense together inside cells, the way oil droplets assemble and separate from water in a vinaigrette.

Key Points: 
  • In human cells, "liquid-liquid phase separation" occurs because similar, large molecules glom together into dense droplets separated from the more diluted parts of the fluid cell interior.
  • Researchers compare condensates to microprocessors, computers built into circuits, because both recognize and calculate responses based on incoming information.
  • Kinases are protein switches that influence cellular processes by phosphorylating attaching a molecule called a phosphate group to target molecules.
  • Finally, the researchers also hope that their findings advance the design of other cellular computers that react to physical forces.

FONDAZIONE PRADA PRESENTS "HUMAN BRAINS: PRESERVING THE BRAIN - FORUM ON NEURODEGENERATIVE DISEASES"

Retrieved on: 
Tuesday, September 6, 2022
Harvard Medical School, Lists of diseases, Max Planck Institute of Neurobiology, Helmholtz Association, University, University College London, Consciousness, Fondazione Prada, Research, Exhibition, Multiple sclerosis, Tianjin Medical University General Hospital, DZNE, Amyotrophic lateral sclerosis, Cone Health Women's Hospital, Lebanese Army Teaching Institute, German Center for Neurodegenerative Diseases, Yale School of Medicine, Weizmann Institute of Science, Organization, Alzheimer's disease, Neurodegeneration, Hospital, Neurology, History, Knowledge, Association, Human, Medical device, Pharmaceutical industry, Medicine, Brain, Brigham, Neuroscience

The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.

Key Points: 
  • The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.
  • "Preserving the Brain" aims to stimulate an open and critical exchange between internationalscientists and experts on neurodegenerative diseases, such as Alzheimer's, Parkinson's,Amyotrophic lateral sclerosis and Multiple sclerosis, which are widely spread and as yetincurable.
  • 'Preserving the Brain' also demonstrates how critical collaboration and sharing of knowledge are within the scientific community.
  • The pivotal moment of "Preserving the Brain" will be the scientific conference held on 6 and 7 October 2022, at Fondazione Prada's Cinema in Milan.

FONDAZIONE PRADA PRESENTS "HUMAN BRAINS: PRESERVING THE BRAIN - FORUM ON NEURODEGENERATIVE DISEASES"

Retrieved on: 
Tuesday, September 6, 2022
Harvard Medical School, Lists of diseases, Max Planck Institute of Neurobiology, Helmholtz Association, University, University College London, Consciousness, Fondazione Prada, Research, Exhibition, Multiple sclerosis, Tianjin Medical University General Hospital, DZNE, Amyotrophic lateral sclerosis, Cone Health Women's Hospital, Lebanese Army Teaching Institute, German Center for Neurodegenerative Diseases, Yale School of Medicine, Weizmann Institute of Science, Organization, Alzheimer's disease, Neurodegeneration, Hospital, Neurology, History, Knowledge, Association, Human, Medical device, Pharmaceutical industry, Medicine, Brain, Brigham, Neuroscience

The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.

Key Points: 
  • The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.
  • "Preserving the Brain" aims to stimulate an open and critical exchange between internationalscientists and experts on neurodegenerative diseases, such as Alzheimer's, Parkinson's,Amyotrophic lateral sclerosis and Multiple sclerosis, which are widely spread and as yetincurable.
  • 'Preserving the Brain' also demonstrates how critical collaboration and sharing of knowledge are within the scientific community.
  • The pivotal moment of "Preserving the Brain" will be the scientific conference held on 6 and 7 October 2022, at Fondazione Prada's Cinema in Milan.

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, C9orf72, Death, German Center for Neurodegenerative Diseases, Patient, Dementia, DPT, Influenza, Research, University, Brain, Bill & Melinda Gates Foundation, Man, Spinal cord, Paralysis, Union, Disease, ALS, Association, DZNE, Parkinson's disease, CDMO, Immune system, Infection, Motor neuron, Woman, Risk, Helmholtz Association, Neurodegeneration, Technology, Antibody, Nervous system, Neuron, Motor neuron disease, Human, Frontotemporal dementia, Pathology, Vaccine, Alzheimer's disease, Vaccination, Movement disorders, Mutation, WHO, Pharmaceutical industry, EU, Haemophilus influenzae

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, C9orf72, Death, German Center for Neurodegenerative Diseases, Patient, Dementia, DPT, Influenza, Research, University, Brain, Bill & Melinda Gates Foundation, Man, Spinal cord, Paralysis, Union, Disease, ALS, Association, DZNE, Parkinson's disease, CDMO, Immune system, Infection, Motor neuron, Woman, Risk, Helmholtz Association, Neurodegeneration, Technology, Antibody, Nervous system, Neuron, Motor neuron disease, Human, Frontotemporal dementia, Pathology, Vaccine, Alzheimer's disease, Vaccination, Movement disorders, Mutation, WHO, Pharmaceutical industry, EU, Haemophilus influenzae

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, Biology, Psychiatric diagnosis, University of Bonn, German Center for Neurodegenerative Diseases, Neurodegenerative disorders, Neurodegeneration, Alzheimer's disease, Parkinson's disease, Caghan Kizil

DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases.

Key Points: 
  • DZNE is a world-leading interdisciplinary public research organization constituted with ten research sites in Germany that investigates methods for prevention, diagnosis and treatment against neurodegenerative diseases.
  • The collaboration will incorporate DZNE's expertise in the fundamental and clinical research with Eisai's abundant experience in drug discovery for neurodegenerative diseases to accelerate development of novel drug candidates.
  • We think that this collaboration will be able to accelerate creation of new treatments for neurodegenerative disorders, including those for Alzheimer's and Parkinson's.
  • The DZNE investigates all aspects of neurodegenerative diseases in order to develop novel approaches of prevention, treatment, and health care.